1 Citation (Scopus)

Abstract

Research on the use of plants for production of protein-based therapeutics has increased tremendously since the initial experiments in the early 1990s. Plant-based expression systems offer several production advantages of low cost, rapidity, scalability, and a significantly lower chance of contamination with prion or mammalian viruses. In addition, the capability of plants in producing homogeneous N-glycans allows the development of novel therapeutics with superior efficacy and safety to their mammalian cell-produced counterparts. Various plant species have been used to develop and produce vaccines, antibodies, and pharmaceutical enzymes against a myriad of diseases by multiple expression technologies. While most of these plant-made therapeutics are in preclinical development, many have progressed into human clinical study phases and several have been approved by regulatory agencies. The current status and recent advancement of plant-based expression systems and key clinical products will be presented in this chapter. The remaining challenges and future directions for the field of plant-made therapeutics will be discussed.

Original languageEnglish (US)
Title of host publicationTransgenic Plants
PublisherAcademic Press Inc
Pages207-244
Number of pages38
DOIs
StatePublished - Jan 1 2018

Publication series

NameAdvances in Botanical Research
Volume86
ISSN (Print)0065-2296

Fingerprint

therapeutics
prions
clinical trials
polysaccharides
vaccines
drugs
viruses
antibodies
enzymes
proteins
cells

Keywords

  • Flavivirus
  • Monoclonal antibody
  • Nicotiana benthamiana
  • Plant expression system
  • Plant-made biologics
  • Plant-made pharmaceutical
  • Therapeutic enzymes
  • Transient expression
  • Vaccine
  • Virus-like particle

ASJC Scopus subject areas

  • Plant Science

Cite this

Chen, Q. (2018). Recombinant Therapeutic Molecules Produced in Plants. In Transgenic Plants (pp. 207-244). (Advances in Botanical Research; Vol. 86). Academic Press Inc. https://doi.org/10.1016/bs.abr.2017.11.006

Recombinant Therapeutic Molecules Produced in Plants. / Chen, Qiang.

Transgenic Plants. Academic Press Inc, 2018. p. 207-244 (Advances in Botanical Research; Vol. 86).

Research output: Chapter in Book/Report/Conference proceedingChapter

Chen, Q 2018, Recombinant Therapeutic Molecules Produced in Plants. in Transgenic Plants. Advances in Botanical Research, vol. 86, Academic Press Inc, pp. 207-244. https://doi.org/10.1016/bs.abr.2017.11.006
Chen Q. Recombinant Therapeutic Molecules Produced in Plants. In Transgenic Plants. Academic Press Inc. 2018. p. 207-244. (Advances in Botanical Research). https://doi.org/10.1016/bs.abr.2017.11.006
Chen, Qiang. / Recombinant Therapeutic Molecules Produced in Plants. Transgenic Plants. Academic Press Inc, 2018. pp. 207-244 (Advances in Botanical Research).
@inbook{2c73dc7d7cde4b61a84087c940a21419,
title = "Recombinant Therapeutic Molecules Produced in Plants",
abstract = "Research on the use of plants for production of protein-based therapeutics has increased tremendously since the initial experiments in the early 1990s. Plant-based expression systems offer several production advantages of low cost, rapidity, scalability, and a significantly lower chance of contamination with prion or mammalian viruses. In addition, the capability of plants in producing homogeneous N-glycans allows the development of novel therapeutics with superior efficacy and safety to their mammalian cell-produced counterparts. Various plant species have been used to develop and produce vaccines, antibodies, and pharmaceutical enzymes against a myriad of diseases by multiple expression technologies. While most of these plant-made therapeutics are in preclinical development, many have progressed into human clinical study phases and several have been approved by regulatory agencies. The current status and recent advancement of plant-based expression systems and key clinical products will be presented in this chapter. The remaining challenges and future directions for the field of plant-made therapeutics will be discussed.",
keywords = "Flavivirus, Monoclonal antibody, Nicotiana benthamiana, Plant expression system, Plant-made biologics, Plant-made pharmaceutical, Therapeutic enzymes, Transient expression, Vaccine, Virus-like particle",
author = "Qiang Chen",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/bs.abr.2017.11.006",
language = "English (US)",
series = "Advances in Botanical Research",
publisher = "Academic Press Inc",
pages = "207--244",
booktitle = "Transgenic Plants",

}

TY - CHAP

T1 - Recombinant Therapeutic Molecules Produced in Plants

AU - Chen, Qiang

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Research on the use of plants for production of protein-based therapeutics has increased tremendously since the initial experiments in the early 1990s. Plant-based expression systems offer several production advantages of low cost, rapidity, scalability, and a significantly lower chance of contamination with prion or mammalian viruses. In addition, the capability of plants in producing homogeneous N-glycans allows the development of novel therapeutics with superior efficacy and safety to their mammalian cell-produced counterparts. Various plant species have been used to develop and produce vaccines, antibodies, and pharmaceutical enzymes against a myriad of diseases by multiple expression technologies. While most of these plant-made therapeutics are in preclinical development, many have progressed into human clinical study phases and several have been approved by regulatory agencies. The current status and recent advancement of plant-based expression systems and key clinical products will be presented in this chapter. The remaining challenges and future directions for the field of plant-made therapeutics will be discussed.

AB - Research on the use of plants for production of protein-based therapeutics has increased tremendously since the initial experiments in the early 1990s. Plant-based expression systems offer several production advantages of low cost, rapidity, scalability, and a significantly lower chance of contamination with prion or mammalian viruses. In addition, the capability of plants in producing homogeneous N-glycans allows the development of novel therapeutics with superior efficacy and safety to their mammalian cell-produced counterparts. Various plant species have been used to develop and produce vaccines, antibodies, and pharmaceutical enzymes against a myriad of diseases by multiple expression technologies. While most of these plant-made therapeutics are in preclinical development, many have progressed into human clinical study phases and several have been approved by regulatory agencies. The current status and recent advancement of plant-based expression systems and key clinical products will be presented in this chapter. The remaining challenges and future directions for the field of plant-made therapeutics will be discussed.

KW - Flavivirus

KW - Monoclonal antibody

KW - Nicotiana benthamiana

KW - Plant expression system

KW - Plant-made biologics

KW - Plant-made pharmaceutical

KW - Therapeutic enzymes

KW - Transient expression

KW - Vaccine

KW - Virus-like particle

UR - http://www.scopus.com/inward/record.url?scp=85043366363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043366363&partnerID=8YFLogxK

U2 - 10.1016/bs.abr.2017.11.006

DO - 10.1016/bs.abr.2017.11.006

M3 - Chapter

AN - SCOPUS:85043366363

T3 - Advances in Botanical Research

SP - 207

EP - 244

BT - Transgenic Plants

PB - Academic Press Inc

ER -